1Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23: 462–477.
2.Messinis, I E. Ovulation induction: a mini review. Hum Reprod 2005; 20: 2688–2697.
3.Messinis, I E, Milingos, S D. Current and future status of ovulation induction in polycystic ovary syndrome. Hum Reprod Update 1997; 3: 235–253.
4.Galazis, N, Zertalis, M, Haoula, Z, et al. Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review. J Obstet Gynaecol 2011; 31: 566–571.
5.Smith, Y R, Randolph, J F Jr, Christman, G M, et al. Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction. Fertil Steril 1998; 70: 165–168.
6.Coughlan, C, Fitzgerald, J, Milne, P, et al. Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities? J Obstet Gynaecol 2010; 30: 393–396.
7.Adashi, E Y. Ovulation induction: clomiphene citrate. In: Adashi, E Y, Rock, J A, Rosenwaks, Z, eds. Reproductive Endocrinology, Surgery and Technology. Lippincott-Raven, Philadelphia. 1996; 1181–1206.
8.Messinis, I E, Nillius, S J. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet Gynecol Scand 1982; 61: 377–379.
9.de Paula Guedes Neto, E, Savaris, R F, von Eye Corleta, H, et al. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril 2011; 96: 769–773.
10.The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998; 83: 1507–1514.
11.Messinis, I E, Bergh, T, Wide, L. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril 1988; 50: 31–35.
12.Franks, S, Adams, J, Mason, H, et al. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985; 12: 605–632.
13.Christin-Maitre, S, Hugues, JN, Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003; 18: 1626–1631.
14.Shoham, Z, Di Carlo, C, Patel, A, et al. Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements. Fertil Steril 1991; 56: 836–841.
15.Baird, D T. Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician’s point of view. Hum Reprod 2001; 16: 1316–1318.
16.Loumaye, E, Engrand, P, Shoham, Z, et al. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314–322.
17.Casper, R F, Mitwally, M F. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol 2011; 54: 685–695.
18.Franik, S, Kremer, J A, Nelen, W L, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; 2: CD010287.
19.Farquhar, C, Brown, J, Marjoribanks, J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2012; 6: CD001122.
20.Amer, S A, Li, T C, Metwally, M, et al. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod 2009; 24: 219–225.
21.Mercorio, F, Mercorio, A, Di Spiezio Sardo, A, et al. Evaluation of ovarian adhesion formation after laparoscopic ovarian drilling by second-look minilaparoscopy. Fertil Steril 2008; 89: 1229–1233.
22.Api, M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol 2009; 25: 159–165.
23.Legro, R S, Barnhart, H X, Schlaff, W D, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551–566.
24.Moll, E, Bossuyt, P M, Korevaar, J C, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. Br Med J 2006; 332: 1485.
25.Moll, E, van der Veen, F, van Wely, M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007; 13: 527–537.
26.Swanton, A, Storey, L, McVeigh, E, et al. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol 2010; 149: 68–71.
27.Kodama, H, Fukuda, J, Karube, H, et al. High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod 1995; 10: 1962–1967.
28.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.
29.Aflatoonian, A, Oskouian, H, Ahmadi, S, et al. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm). J Assist Reprod Genet 2009; 26: 319–325.
30.Jayaprakasan, K, Chan, Y, Islam, R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012; 98: 657–663.
31.Vendola, K A, Zhou, J, Wang, J, et al. Androgens stimulate primordial follicle development in the primate ovary. Biol Reprod 1999; 61: 353–357.
32.Dale, P O, Tanbo, T, Haug, E, et al. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod 1998; 13: 567–570.
33.Neulen, J, Yan, Z, Raczek, S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967–1971.
34.Gómez, R, Ferrero, H, Delgado-Rosas, F, et al. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab 2011; 96: 2484–2492.
35.Al-Inany, H G, Youssef, M A, Aboulghar, M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; CD001750.
36.Lin, H, Li, Y, Li, L, et al. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS ONE 2014; 9: e91796.
37.Vrtacnik-Bokal, E, Virant Klun, I, Verdenik, I. Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. Reprod Biomed Online 2009; 18: 21–28.
38.Itskovitz, J, Boldes, R, Levron, J, et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213–220.
39.Cerrillo, M, Pacheco, A, Rodríguez, S, et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril 2011; 95: 2517–2519.
40.Castillo, J C, Dolz, M, Bienvenido, E, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010; 20: 175–181.
41.Engmann, L, DiLuigi, A, Schmidt, D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84–91.
42.Shapiro, B S, Daneshmand, S T, Garner, F C, et al. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011; 95: 2715–2717.
43.Humaidan, P, Ejdrup Bredkjaer, H, Westergaard, L G, et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847–854.
44.Radesic, B, Tremellen, K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011; 26: 3437–3442.
45.Iliodromiti, S, Blockeel, C, Tremellen, K P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 2013; 28: 2529–2536.
46.Haas, J, Kedem, A, Machtinger, R, et al. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels – a proof of concept. J Ovarian Res 2014; 7: 35.
47.Roque, M, Lattes, K, Serra, S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 2013; 99: 156–162.
48.Seyhan, A, Ata, B, Polat, M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013; 28: 2522–2528.
49.Humaidan, P, Thomsen, L H, Alsbjerg, B. GnRH a trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. Hum Reprod 2013; 28: 2593–2594.
50.Fatemi, H M, Popovic-Todorovic, B, Humaidan, P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 2014; 101: 1008–1011.
51.Heijnen, E M, Eijkemans, M J, De Klerk, C, et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369: 743–749.
52.Palomba, S, Falbo, A, Carrillo, L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96: 1384–1390.
53.Palomba, S, Falbo, A, La Sala, G B. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. Br J Obstet Gynaecol 2013; 120: 267–276.
54.Leitao, V M, Moroni, R M, Seko, L M, et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014; 101: 664–675.
55.Gurgan, T, Demirol, A, Guven, S, et al. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 2011; 96: 53–57.